Primary open-angle glaucoma Cancer Primary open-angle glaucoma
Conditions
Interventions
Following the monitoring of the baseline or washout IOP and BP all study patients were randomly assigned to receive either one drop of TDFC twice daily (08:00 and 20:00) or one drop of latanoprost onc
Bio-Rad, USA). At each timepoint, the mean of 3 consecutive readings was calculated.
Ambulatory blood pressure monitoring was recorded by means of an automated portable BP device, TM-2430 (A&D Co, S
Sponsors
Clinica Oculistica (Italy)
Eligibility
Inclusion criteria
Inclusion criteria: We enrolled in the present study consecutive newly diagnosed and previously untreated POAG patients who demonstrated typical optic disc excavation and visual field abnormalities. We included POAG patients older than 45 years with no previous history of ocular surgery or laser. Additional inclusion criteria were: 1. Open-angle by gonioscopy (Grade III-IV according to Shaffer?s grading system) 2. Untreated diurnal IOP between 23 and 32 mm Hg (mean of the two highest values recorded in a daytime IOP curve with measurements every 2 hours between 08:00 and 18:00 by a calibrated Goldmann applanation tonometry) 3. Visual acuity 20/40 or better 4. Mean defect >6 dB using the Humphrey 24-2 program (Humphrey Visual Field Analyzer model 745 perimeter, Humphrey Instruments, Inc., USA) 5. No history of allergy to the ingredients of any of the study drugs 6. No history of cardiovascular disease (e.g. arterial hypertension, heart disease, arrhythmia) 7. No concomitant systemic treatment (e.g. beta-blockers, angiotensin-converting enzyme inhibitors) that could modify IOP, or blood pressure. 8. Females were enrolled in the study only if they were postmenopausal or were using contraceptives
Exclusion criteria
Exclusion criteria: See inclusion criteria
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The following were measured at baseline, and at the end of each treatment period: 1. 24-hour IOP 2. Ambulatory BP 3. Calculated DOPP | — |
Secondary
| Measure | Time frame |
|---|---|
| Adverse events | — |
Countries
Italy
Outcome results
None listed